Stream Neuroscience co-founder & CEO speaks about clinical utility of brain organoid research for drug discovery.
Publication is no longer available online
Stream Neuroscience co-founder & CEO panelist at NEUROVATION: Scientist to Entrepreneur Panel,
This panel will feature researchers from HBI who have gone on to launch biotech startups from their research. They will share insights into their journeys, their discoveries, how they created a product, and how they are developing that product to benefit the community. They will also share some lessons learned along the way. Read on […]
Stream Neuroscience co-founder and CEO invited speaker at EMBO (Karnataka, India)
Presenting on the use of brain organoids to study Dravet Syndrome.
Stream Neuroscience co-founder & CEO presents at Banff International Epilepsy Symposium (Banff, AB) on pipelines to new anti-seizure drug therapies.
The 4th Banff International Epilepsy Symposium, a satellite event of the 2nd North American Epilepsy Congress, will take place in a virtual format on 6 May 2022.
ASTech Award, Outstanding Women in Innovation
2021 Winner: Outstanding Woman in Innovation sponsored by TSGI Corporation
Stream Neuroscience co-founder and CEO keynote speaker at NeuroNexus (Virtual) on Machine learning in neuroscience and drug discovery research.
Neuro Nexus is a multidisciplinary design competition that aims to bridge the gap between disciplines, accelerate research, and improve the translation of new ideas to impact neuroscience, neurological disorders and mental health.
Metabolism-based drug discovery in zebrafish: An emerging strategy to uncover new anti-seizure therapies.
Ibhazehiebo, K, et al., 2020 May
Metabolism-based drug discovery in zebrafish: an emerging strategy to uncover new anti-seizure therapies.
Ibhazehiebo K, Rho JM, Kurrasch DM — 2020
Stream Neuroscience co-founder & CEO speaks at 14th International Zebrafish Conference (Suzhou, China)
Dr. Kurrasch will present “Screening to Clinical trials: The power of zebrafish in epilepsy discovery.”
Design and synthesis of selective phosphodiesterase 4D (PDE4D) allosteric inhibitors for the treatment of Fragile X Syndrome and other brain disorders.
Gurney, ME, et al. J Med Chem. 2019 May